PuSH - Publication Server of Helmholtz Zentrum München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Tsiverioti, C.A.* ; Gottschlich, A.* ; Trefny, M.P.* ; Theurich, S.* ; Anders, H.J.* ; Kroiss, M.* ; Kobold, S.

Beyond CAR T cells: exploring alternative cell sources for CAR-like cellular therapies.

Biol. Chem., DOI: 10.1515/hsz-2023-0317 (2024)
Publ. Version/Full Text DOI PMC
Open Access Hybrid
Creative Commons Lizenzvertrag
Chimeric antigen receptor (CAR)-T cell therapy has led to remarkable clinical outcomes in the treatment of hematological malignancies. However, challenges remain, such as limited infiltration into solid tumors, inadequate persistence, systemic toxicities, and manufacturing insufficiencies. The use of alternative cell sources for CAR-based therapies, such as natural killer cells (NK), macrophages (MΦ), invariant Natural Killer T (iNKT) cells, γδT cells, neutrophils, and induced pluripotent stem cells (iPSC), has emerged as a promising avenue. By harnessing these cells' inherent cytotoxic mechanisms and incorporating CAR technology, common CAR-T cell-related limitations can be effectively mitigated. We herein present an overview of the tumoricidal mechanisms, CAR designs, and manufacturing processes of CAR-NK cells, CAR-MΦ, CAR-iNKT cells, CAR-γδT cells, CAR-neutrophils, and iPSC-derived CAR-cells, outlining the advantages, limitations, and potential solutions of these therapeutic strategies.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Altmetric
2.900
0.000
1
Tags
Annotations
Special Publikation
Hide on homepage

Edit extra information
Edit own tags
Private
Edit own annotation
Private
Hide on publication lists
on hompage
Mark as special
publikation
Publication type Article: Journal article
Document type Review
Keywords Car-nk Cells ; Car-t Cells ; Car-inkt Cells ; Car-macrophages ; Car-neutrophils ; Car-γδt cells; Chimeric-antigen-receptor; Natural-killer-cells; Pluripotent Stem-cells; V-alpha-24-invariant Nkt Cells; Acute Myeloid-leukemia; In-vivo Expansion; Phase-i; Dendritic Cells; Adoptive Immunotherapy; Antitumor-activity
Language english
Publication Year 2024
HGF-reported in Year 2024
ISSN (print) / ISBN 1431-6730
e-ISSN 1437-4315
Journal Biological Chemistry
Publisher de Gruyter
Publishing Place Genthiner Strasse 13, D-10785 Berlin, Germany
Reviewing status Peer reviewed
Institute(s) Unit for Clinical Pharmacology (KKG-EKLiP)
POF-Topic(s) 30203 - Molecular Targets and Therapies
Research field(s) Immune Response and Infection
PSP Element(s) G-522100-001
Grants Go-Bio-Initiative
DOI 10.1515/hsz-2023-0317
WOS ID 001227430400001
PubMed ID 38766710
Erfassungsdatum 2024-06-14
[➜Report correction]